icon on The FDA recently released a significant decision that will impact GLP-1 drugs, delisting semaglutide and tirzepatide from its shortage list - leading to heavy restrictions of compounded weight loss drugs often sold by online and telehealth pharmacies.
The decision is a big win for pharma companies Lilly and Novo.
Kevin Shortsle spoke to Amy Baxter of PharmaVoice about what this now means for the two companies, and how this might impact consumers.
Read the full article here: Lilly, Novo expand DTC reach of obesity meds after compound win | PharmaVoice.
Briefcase
Page Order
Page name
Reorder
Remove
Practices
Alternative Dispute Resolution Business & Corporate Corporate Transparency Act Business and Corporate Tax Tax Credits and Incentives Business Bankruptcy & Creditors' Rights Data Privacy and Cybersecurity Employee Benefits Environmental Franchising Intellectual Property Patent Trademark Copyright Intellectual Property Litigation Labor & Employment Litigation Business Litigation Intellectual Property Mergers & Acquisitions Real Estate Securities Trust & Estate PlanningIntellectual Property Legal Services & Attorneys I APRIL 7, 2025
Lilly, Novo expand DTC reach of obesity meds after compound win
Related Media
2
January
17
July
5
January
27
November
6
July
18
May
1
May
19
April
13
April
7
March
13
February
13
February
10
February
31
January
29
November
8
November
18
October
7
September
10
August
30
June
14
June
14
June
8
June
31
May
6
May
4
May
7
March
4
March
8
February
17
January
28
October
20
September
27
July
19
July
15
July
23
June
9
March
21
December
1
December
25
September
25
July
1
April
29
October
15
August
19
January
15
December
6
April
9
June
1
June
12
April
1
November
1
September
27
July
26
January
1
September
1
September
We're more than just business lawyers.
We're lawyers for your business.
From startup to maturity, we help businesses grow and succeed—assisting them with getting deals done,
resolving disputes, and complying with rules and regulations.